Long-term Health Outcomes Among Survivors Exposed to Sulfur Mustard in Iran.
Adult
Chemical Warfare Agents
/ toxicity
Eye Diseases
/ chemically induced
Female
Hospitalization
/ statistics & numerical data
Humans
Iran
/ epidemiology
Lung Diseases
/ chemically induced
Male
Mustard Gas
/ toxicity
Prevalence
Severity of Illness Index
Sex Factors
Skin Diseases
/ chemically induced
Survivors
/ statistics & numerical data
Time
War Exposure
/ adverse effects
Journal
JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235
Informations de publication
Date de publication:
01 12 2020
01 12 2020
Historique:
entrez:
10
12
2020
pubmed:
11
12
2020
medline:
30
1
2021
Statut:
epublish
Résumé
The prevalence and severity of long-term health complications after exposure to sulfur mustard are unknown. To investigate the long-term health outcomes among survivors exposed to sulfur mustard during the Iran-Iraq War. In this retrospective cohort study, late-onset health complications of 64 190 Iranian survivors exposed to sulfur mustard during the Iran-Iraq War from 1980 to 1988 were investigated using descriptive statistics. Data involving affected organs and symptom severity were extracted from the Veterans and Martyr Affair Foundation (VMAF) database from 1980 to 2019. Assessments were conducted across 3 groups depending on whether survivors were (1) evacuated and admitted (EA) to a hospital; (2) not evacuated or admitted (NEA) to a hospital; or (3) evacuation or admission status was not documented. Analysis of chronic symptom severity following exposure to sulfur mustard. Mild, moderate, or severe rankings of symptoms in lungs, eyes, and skin of survivors exposed to sulfur mustard using data from the VMAF database. Of 64 190 chemical survivors registered in the VMAF database, 60 861 met the inclusion criteria. Of the included survivors, 98.0% were male, and the mean (SD) age was 23.5 (7.7) years. Most survivors (53 675 [88.2%]) had no symptoms or mild lesions, and 7186 survivors (11.8%) had moderate or severe complications. Moderate to severe lung (6540 [10.7%]), eye (335 [0.6%]), or skin (725 [1.2%]) injuries were documented in the exposed population. The proportion of moderate plus severe late complications in eyes was 3 times as high in male survivors compared with female survivors (0.6% [95% CI, 0.53%-0.65%] vs 0.2% [95% CI, 0.09%-0.73%]; P < .001), whereas dermal complications were significantly more common in female survivors (3.9% [95% CI, 2.92%-5.11%] vs 1.14% [95% CI, 1.06%-1.23%]; P < .001). Mild lung lesions were more prevalent in the NEA group than in the EA group (73.9% [95% CI, 73.4%-74.4%] vs 11.0% [95% CI, 10.6%-11.3%]; P < .001). In the NEA group, 83.2% (n = 23 866) developed lung injuries that were mostly mild or moderate, whereas 77% (n = 24 766) of the EA group did not develop lung injuries (P < .001). The present study found sex differences in the frequencies of eye and skin complications following sulfur mustard exposure, and lung complications were more prevalent years after sulfur mustard exposure than soon after exposure. Mild lung lesions were observed more frequently among sulfur mustard-exposed survivors who had not been evacuated or hospitalized than among those who had been evacuated or hospitalized. These differences may be due to physiological response or dose of exposure. Close monitoring over an extended period may be required for detection of late pulmonary complications in individuals exposed to sulfur mustard.
Identifiants
pubmed: 33301016
pii: 2773969
doi: 10.1001/jamanetworkopen.2020.28894
pmc: PMC7729433
doi:
Substances chimiques
Chemical Warfare Agents
0
Mustard Gas
T8KEC9FH9P
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e2028894Références
Chest. 1997 Sep;112(3):734-8
pubmed: 9315808
JAMA. 1989 Aug 4;262(5):640-3
pubmed: 2746816
Fundam Appl Toxicol. 1984 Apr;4(2 Pt 2):S71-83
pubmed: 6233199
Respir Med. 2006 Jan;100(1):115-22
pubmed: 15893923
Cutan Ocul Toxicol. 2009;28(2):71-7
pubmed: 19514930
Clin Exp Ophthalmol. 2006 May-Jun;34(4):342-6
pubmed: 16764654
Arch Iran Med. 2009 Jan;12(1):5-14
pubmed: 19111023
Basic Clin Pharmacol Toxicol. 2006 Oct;99(4):273-82
pubmed: 17040211
Cancer Causes Control. 2013 Jan;24(1):99-105
pubmed: 23184123
Postgrad Med. 2002 Oct;112(4):90-6; quiz 4
pubmed: 12400151
Daru. 2012 Sep 10;20(1):27
pubmed: 23351279
Cutan Ocul Toxicol. 2012 Sep;31(3):241-9
pubmed: 22122127
J Appl Toxicol. 2000 Dec;20 Suppl 1:S63-72
pubmed: 11428645
J Clin Epidemiol. 2015 Dec;68(12):1463-71
pubmed: 26112433
Cutan Ocul Toxicol. 2012 Sep;31(3):214-9
pubmed: 22187952
Arch Belg. 1984;Suppl:302-10
pubmed: 6535480
J Occup Environ Med. 2003 Nov;45(11):1136-43
pubmed: 14610394
J Thorac Dis. 2019 Apr;11(4):1303-1315
pubmed: 31179072
Fundam Clin Pharmacol. 2005 Dec;19(6):713-21
pubmed: 16313284